

Prof. Dr. Uwe Haberkorn

Director Dept. Nuclear Medicine, Heidelberg
Head Clinical Cooperation Unit Nuclear Medicine, DKFZ



21.9.1959

Dept of Nuclear Medicine
Im Neuenheimer Feld 400
69120 Heidelberg

06221 56 7731 (phone)

06221 56 5473 (fax)

uwe.haberkorn@med.uni-heidelberg.de

SCIENTIFIC VITA:

- 1979-1982 Studies in Philosophy and German literature at the University of Heidelberg
- 1982-1988 Studies in medicine at the universities of Marburg, Würzburg and Heidelberg
- 1985-1988 M.D. degree: correlation of ultrasound image pattern and liver tissue properties in excised livers
- 1988-1998 Research physician at the department of Oncological Diagnostics and therapy (Prof. Dr. G. van Kaick) at the Deutsches Krebsforschungszentrum Heidelberg
- 1995 Board Certification in Nuclear medicine
- 1996 Habilitation thesis
- since 1998 Professor of Nuclear medicine at the University of Heidelberg, Head of the Dept. of Nuclear Medicine, University of Heidelberg, Head of the Clinical Cooperation Unit Nuclear Medicine at the Deutsches Krebsforschungszentrum Heidelberg

AWARDS:

Posterpreis der Europäischen Röntgengesellschaft (1991); Posterpreis der Deutschen Gesellschaft für Nuklearmedizin (1995); Mallinckrodt Preis der Deutschen Gesellschaft für Nuklearmedizin (1996); Posterpreis der Deutschen Röntgengesellschaft (1997); 1. Preis für Kontrastmittelforschung von der Deutschen Röntgengesellschaft (1998); Posterpreis der Deutschen Röntgengesellschaft (1999); Posterpreis der Deutschen Gesellschaft für Nuklearmedizin für das beste wissenschaftliche Poster (2004)

FIELDS OF INTEREST:

Nuclear medicine; gene therapy; tumor metabolism; antiangiogenesis; biotechnology

SELECTED PUBLICATIONS (since 2000)

Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L, Zhu R, Haberkorn U (2006). Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene. **J Nucl Med** 47, 854-862

Askoxyllakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U (2005). Preclinical evaluation of the breast cancer cell binding peptide p160. **Clin Cancer Res** 11, 6705-6712

Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U (2005). A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. **Clin Cancer Res** 11, 139-146

Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Vorwald S, Eskerski H, Eisenhut M, Metz J, Kinscherf R, Haberkorn U (2005). Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. **Clin Cancer Res** 11, 2132-2140

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Maecke HR, Eisenhut M, Debus J, Haberkorn U (2005). Characterization of ⁶⁸Ga DOTA-D-Phe¹-Tyr³-Octreotide Kinetics in Patients with Meningiomas. **J Nucl Med** 46, 763-769

Altmann A, Schulz RB, Glensch G, Eskerski H, Zitzmann S, Eisenhut M, Haberkorn U (2005). Effects of Pax8 and TTF-1 Thyroid Transcription Factor Gene Transfer in Hepatoma Cells: Imaging of Functional Protein-Protein Interaction and Iodide Uptake. **J Nucl Med** 46, 831-839

Maecke HR, Hofmann M, Haberkorn U (2005). Gallium-68 Labeled Peptides in Tumor Imaging. **J Nucl Med** 46:172-178

Haberkorn U, Beuter P, Kubler W, Eskerski H, Eisenhut M, Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A, Altmann A (2004). Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. **J Nucl Med** 45, 827-833

Altmann A, Kissel M, Zitzmann S, Kubler W, Mahmut M, Peschke P, Haberkorn U (2003). Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. **J Nucl Med** 44, 973-980

Haberkorn U, Kinscherf R, Kissel M, Kubler W, Mahmut M, Sieger S, Eisenhut M, Peschke P, Altmann A (2003). Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. **Gene Ther** 10, 774-780